rm-493 has been researched along with Multiple-Sclerosis* in 1 studies
1 other study(ies) available for rm-493 and Multiple-Sclerosis
| Article | Year |
|---|---|
Setmelanotide, a Novel, Selective Melanocortin Receptor-4 Agonist Exerts Anti-inflammatory Actions in Astrocytes and Promotes an Anti-inflammatory Macrophage Phenotype.
To date, available treatment strategies for multiple sclerosis (MS) are ineffective in preventing or reversing progressive neurologic deterioration, creating a high, and unmet medical need. One potential way to fight MS may be by limiting the detrimental effects of reactive astrocytes, a key pathological hallmark for disease progression. One class of compounds that may exert beneficial effects via astrocytes are melanocortin receptor (MCR) agonists. Among the MCR, MC4R is most abundantly expressed in the CNS and several rodent studies have described that MC4R is-besides neurons-expressed by astrocytes. Activation of MC4R in astrocytes has shown to have potent anti-inflammatory as well as neuroprotective effects Topics: Adult; Aged; alpha-MSH; Anti-Inflammatory Agents; Astrocytes; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Female; Humans; Interleukin-11; Interleukin-6; Macrophages; Male; Middle Aged; Multiple Sclerosis; Phenotype; Phosphorylation; Receptor, Melanocortin, Type 4 | 2019 |